Cellectis (CLLS) Cash from Operations Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 158.60% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 10.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.20% |
| Dec 31, 2025 | -21,942.55% |
| Sep 30, 2025 | 73.05% |
| Jun 30, 2025 | -119.76% |
| Mar 31, 2025 | 26.40% |
| Dec 31, 2024 | -100.11% |
| Sep 30, 2024 | 65.90% |
| Jun 30, 2024 | 374.01% |
| Mar 31, 2024 | 17.69% |
| Dec 31, 2023 | 3,654.10% |
| Sep 30, 2023 | 34.36% |
| Jun 30, 2023 | 19.20% |
| Mar 31, 2023 | 22.63% |
| Dec 31, 2022 | 94.21% |
| Sep 30, 2022 | 14.41% |
| Jun 30, 2022 | -94.38% |
| Mar 31, 2022 | 10.55% |
| Dec 31, 2021 | 37.79% |
| Sep 30, 2021 | -18.81% |
| Jun 30, 2021 | 45.44% |
| Mar 31, 2021 | -2,907.20% |
| Dec 31, 2020 | -363.38% |
| Sep 30, 2020 | -13.07% |
| Jun 30, 2020 | -4.76% |
| Mar 31, 2020 | 106.51% |
| Dec 31, 2019 | 64.50% |
| Sep 30, 2019 | -50.86% |
| Jun 30, 2019 | -69.12% |
| Mar 31, 2019 | -12.11% |
| Dec 31, 2018 | -116.57% |
| Sep 30, 2018 | 3.10% |
| Jun 30, 2018 | 27.89% |
| Mar 31, 2018 | -22.74% |
| Dec 31, 2017 | -671.69% |
| Sep 30, 2017 | -712.67% |
| Jun 30, 2017 | -61.95% |
| Mar 31, 2017 | 24.68% |
| Dec 31, 2016 | -93.98% |
| Sep 30, 2016 | 62.72% |
| Jun 30, 2016 | 39.88% |
| Mar 31, 2016 | -1,468.99% |